Project Grant R01DA064912
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Texas Medical Branch at Galveston a Project Grant totaling $1,590,180 under the Drug Use and Addiction Research Programs (CFDA 93.279) to support discovery and development of GPR52 (G Protein-Coupled Receptor 52) ligand probes for treating cocaine use disorder (CUD). The five-year project, initiated September 1, 2025 and concluding May 31, 2030, focuses on identifying and characterizing...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Texas Medical Branch at Galveston a $880,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2025, with a completion date of June 30, 2027. This research project investigates GPR6 (G protein-coupled receptor 6) as a novel druggable target for treating cocaine use disorder (CUD). The research deliverables include characterization of GPR6 expression...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA), under its Drug Use and Addiction Research Programs (CFDA 93.279), awarded $877,500 to the University of California, San Diego for a two-year project (July 15, 2025 through June 30, 2027) investigating neurobiological mechanisms underlying cocaine use disorder (CUD) susceptibility. The project employs a novel polygenic prediction methodology called RATTACA to identify pre-existing cellular differences in gabaergic and...
- Federal Grant Award Summary Texas A&M University received a $124,215 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), with an award date of August 11, 2026, and a completion date of February 28, 2029. This research project investigates how circadian rhythms are integrated into neural circuitry governing reward-seeking behavior, with a specific focus on the mesolimbic dopamine pathway. The study examines the...
- Federal Grant Award Summary Vanderbilt University received a $236,664 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic neuroscience research examining the neural mechanisms of cocaine use disorder. The research, titled "Specificity and Stability of Cocaine Ensembles," will be performed at the university's Nashville, Tennessee location from the award date of September 25, 2025, through June...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Francisco a $1.62 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the neural mechanisms supporting sudden insight learning in cue-reward associations. The five-year award, effective July 1, 2025 through March 31, 2030, funds fundamental neuroscience research investigating how distributed brain networks—specifically the...
- Federal Project Grant Award Summary Vanderbilt University received a $2.275 million Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) effective July 1, 2025, through March 31, 2030. The award supports research investigating the molecular determinants of neuronal ensemble recruitment by cocaine within the nucleus accumbens (NAc), a key reward-related brain region. The project examines how lysine acetyltransferase 2A (KAT2A), a...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $181,092 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded May 1, 2026, with completion targeted for April 30, 2028. This K99/R00 career development award supports fundamental neuroscience research investigating dopamine receptor type 2 (D2)-expressing cells in the ventral hippocampus and their role in cocaine relapse...
- Federal Grant Award Summary Duke University received a $1.74M Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 30, 2025, with completion targeted for May 31, 2030. The research initiative, titled "Dissecting and Modulating Cell Type and Circuit-Specific Epigenetic Mechanisms of Cocaine Addiction," will be conducted at the university's Durham, North Carolina facilities. The project...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $6,942,762 on September 30, 2025, through its Drug Use and Addiction Research Programs (CFDA 93.279) to The Research Foundation for the State University of New York, doing business as SUNY Downstate Health Sciences University, to conduct longitudinal research on neighborhood conditions, neural circuits, and substance use behaviors across the early life course. The four-year project, concluding June 30,...
Texas A&M University System Health Science Center received a $675,247 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded June 15, 2026, with completion scheduled for March 31, 2031. The award supports neuroscience research investigating how cocaine exposure dysregulates cholinergic signaling in the dorsomedial striatum, a brain region critical to cognitive flexibility and adaptive decision-making. The project examines the neurobiological mechanisms by which cocaine self-administration impairs reversal learning—the ability to adjust behavior based on changing environmental conditions—through enhanced inhibition of cholinergic interneurons and disrupted acetylcholine signaling. The research deliverables comprise three integrated aims utilizing advanced neuroscientific techniques. Aim 1 defines how cocaine-induced changes in inhibitory signaling affect thalamic excitation of cholinergic interneurons and acetylcholine release through dual-channel optogenetics, electrophysiology, and genetically encoded sensors. Aim 2 determines how cocaine disrupts cholinergic modulation of cortical inputs to the striatum, revealing mechanisms underlying action-outcome updating deficits. Aim 3 characterizes cocaine-induced alterations in acetylcholine dynamics during behavioral reversal tasks in vivo. Collectively, these research activities are expected to advance fundamental understanding of substance use disorder neurobiology and identify potential therapeutic targets for cognitive inflexibility associated with cocaine addiction.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $675.2k | 6/10/26 |